Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib (BOS) in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs)

Andreas Hochhaus; Carla Boquimpani; Delphine Rea; Yosuke Minami; Elza Lomaia; Sergey Voloshin; Anna G. Turkina; Dong Wook Kim; Jane Apperley; Jorge E. Cortes; Andre Abdo; Laura Maria Fogliatto; Dennis Dong Hwan Kim; Philipp D. le Coutre; Susanne Saussele; Mario Annunziata; Timothy P. Hughes; Naeem A. Chaudhri; Lynette C.Y. Chee; Valentín García Gutiérrez; Koji Sasaki; Paola Aimone; Alex Allepuz; Sarah Quenet; Véronique Bédoucha; Michael J. Mauro

doi:10.1182/BLOOD-2020-143816

Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib (BOS) in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs)

Andreas Hochhaus, Carla Boquimpani, Delphine Rea, Yosuke Minami, Elza Lomaia, Sergey Voloshin, Anna G. Turkina, Dong Wook Kim, Jane Apperley, Jorge E. Cortes, Andre Abdo, Laura Maria Fogliatto, Dennis Dong Hwan Kim, Philipp D. le Coutre, Susanne Saussele, Mario Annunziata, Timothy P. Hughes, Naeem A. Chaudhri, Lynette C.Y. Chee, Valentín García GutiérrezKoji Sasaki, Paola Aimone, Alex Allepuz, Sarah Quenet, Véronique Bédoucha, Michael J. Mauro

Medicine

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Original language	English (US)
Journal	Blood
Volume	136
DOIs	https://doi.org/10.1182/BLOOD-2020-143816
State	Published - Nov 19 2020

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/BLOOD-2020-143816

Cite this

Hochhaus, A., Boquimpani, C., Rea, D., Minami, Y., Lomaia, E., Voloshin, S., Turkina, A. G., Kim, D. W., Apperley, J., Cortes, J. E., Abdo, A., Fogliatto, L. M., Kim, D. D. H., le Coutre, P. D., Saussele, S., Annunziata, M., Hughes, T. P., Chaudhri, N. A., Chee, L. C. Y., ... Mauro, M. J. (2020). Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib (BOS) in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs). Blood, 136. https://doi.org/10.1182/BLOOD-2020-143816

Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib (BOS) in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs). / Hochhaus, Andreas; Boquimpani, Carla; Rea, Delphine et al.
In: Blood, Vol. 136, 19.11.2020.

Research output: Contribution to journal › Article › peer-review

Hochhaus, A, Boquimpani, C, Rea, D, Minami, Y, Lomaia, E, Voloshin, S, Turkina, AG, Kim, DW, Apperley, J, Cortes, JE, Abdo, A, Fogliatto, LM, Kim, DDH, le Coutre, PD, Saussele, S, Annunziata, M, Hughes, TP, Chaudhri, NA, Chee, LCY, Gutiérrez, VG, Sasaki, K, Aimone, P, Allepuz, A, Quenet, S, Bédoucha, V & Mauro, MJ 2020, 'Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib (BOS) in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs)', Blood, vol. 136. https://doi.org/10.1182/BLOOD-2020-143816

Hochhaus A, Boquimpani C, Rea D, Minami Y, Lomaia E, Voloshin S et al. Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib (BOS) in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs). Blood. 2020 Nov 19;136. doi: 10.1182/BLOOD-2020-143816

Hochhaus, Andreas ; Boquimpani, Carla ; Rea, Delphine et al. / Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib (BOS) in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs). In: Blood. 2020 ; Vol. 136.

@article{88eb9e08af5246b398b941e52b034984,

title = "Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib (BOS) in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs)",

author = "Andreas Hochhaus and Carla Boquimpani and Delphine Rea and Yosuke Minami and Elza Lomaia and Sergey Voloshin and Turkina, {Anna G.} and Kim, {Dong Wook} and Jane Apperley and Cortes, {Jorge E.} and Andre Abdo and Fogliatto, {Laura Maria} and Kim, {Dennis Dong Hwan} and {le Coutre}, {Philipp D.} and Susanne Saussele and Mario Annunziata and Hughes, {Timothy P.} and Chaudhri, {Naeem A.} and Chee, {Lynette C.Y.} and Guti{\'e}rrez, {Valent{\'i}n Garc{\'i}a} and Koji Sasaki and Paola Aimone and Alex Allepuz and Sarah Quenet and V{\'e}ronique B{\'e}doucha and Mauro, {Michael J.}",

year = "2020",

month = nov,

day = "19",

doi = "10.1182/BLOOD-2020-143816",

language = "English (US)",

volume = "136",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

}

TY - JOUR

T1 - Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib (BOS) in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs)

AU - Hochhaus, Andreas

AU - Boquimpani, Carla

AU - Rea, Delphine

AU - Minami, Yosuke

AU - Lomaia, Elza

AU - Voloshin, Sergey

AU - Turkina, Anna G.

AU - Kim, Dong Wook

AU - Apperley, Jane

AU - Cortes, Jorge E.

AU - Abdo, Andre

AU - Fogliatto, Laura Maria

AU - Kim, Dennis Dong Hwan

AU - le Coutre, Philipp D.

AU - Saussele, Susanne

AU - Annunziata, Mario

AU - Hughes, Timothy P.

AU - Chaudhri, Naeem A.

AU - Chee, Lynette C.Y.

AU - Gutiérrez, Valentín García

AU - Sasaki, Koji

AU - Aimone, Paola

AU - Allepuz, Alex

AU - Quenet, Sarah

AU - Bédoucha, Véronique

AU - Mauro, Michael J.

PY - 2020/11/19

Y1 - 2020/11/19

UR - http://www.scopus.com/inward/record.url?scp=85097785937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85097785937&partnerID=8YFLogxK

U2 - 10.1182/BLOOD-2020-143816

DO - 10.1182/BLOOD-2020-143816

M3 - Article

AN - SCOPUS:85097785937

SN - 0006-4971

VL - 136

JO - Blood

JF - Blood

ER -

Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib (BOS) in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs)

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this